De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Arvinas Beheer

Beheer criteriumcontroles 2/4

De CEO Arvinas' is John Houston, benoemd in Sep2017, heeft een ambtstermijn van 7.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.63M, bestaande uit 8.6% salaris en 91.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.26% van de aandelen van het bedrijf, ter waarde $ 21.32M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 5 jaar.

Belangrijke informatie

John Houston

Algemeen directeur

US$7.6m

Totale compensatie

Percentage CEO-salaris	8.6%
Dienstverband CEO	7.1yrs
Eigendom CEO	1.3%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	5yrs

Recente managementupdates

Recent updates

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

May 05

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Feb 24

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Sep 09

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug 19

Arvinas: Still Holding, Just Not Buying More

May 23

Analyse CEO-vergoeding

Hoe is John Houston's beloning veranderd ten opzichte van Arvinas's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$323m
Mar 31 2024	n/a	n/a	-US$355m
Dec 31 2023	US$8m	US$658k	-US$367m
Sep 30 2023	n/a	n/a	-US$295m
Jun 30 2023	n/a	n/a	-US$298m
Mar 31 2023	n/a	n/a	-US$301m
Dec 31 2022	US$10m	US$632k	-US$282m
Sep 30 2022	n/a	n/a	-US$253m
Jun 30 2022	n/a	n/a	-US$233m
Mar 31 2022	n/a	n/a	-US$213m
Dec 31 2021	US$13m	US$584k	-US$191m
Sep 30 2021	n/a	n/a	-US$180m
Jun 30 2021	n/a	n/a	-US$164m
Mar 31 2021	n/a	n/a	-US$139m
Dec 31 2020	US$8m	US$564k	-US$119m
Sep 30 2020	n/a	n/a	-US$99m
Jun 30 2020	n/a	n/a	-US$86m
Mar 31 2020	n/a	n/a	-US$78m
Dec 31 2019	US$5m	US$528k	-US$70m
Sep 30 2019	n/a	n/a	-US$65m
Jun 30 2019	n/a	n/a	-US$173m
Mar 31 2019	n/a	n/a	-US$179m
Dec 31 2018	US$6m	US$428k	-US$240m
Sep 30 2018	n/a	n/a	-US$233m
Jun 30 2018	n/a	n/a	-US$114m
Mar 31 2018	n/a	n/a	-US$98m
Dec 31 2017	US$954k	US$371k	-US$29m

Compensatie versus markt: De totale vergoeding ($USD 7.63M ) John } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van John is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

John Houston (64 yo)

7.1yrs

Tenure

US$7,627,032

Compensatie

Dr. John G. Houston, Ph.D. serves as Independent Director at NextCure, Inc. since September 10, 2020. He has been President, Chief Executive Officer and Director of Arvinas, Inc. since September 20, 2017 a...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
John Houston	Chairperson	7.1yrs	US$7.63m	1.26% $ 21.9m
Ian Taylor	President of Research & Development and Chairman of Scientific Advisory Board	less than a year	US$2.73m	0.14% $ 2.4m
Andrew Saik	CFO & Treasurer	less than a year	geen gegevens	geen gegevens
David Loomis	VP, Chief Accounting Officer & Corporate Controller	1.8yrs	geen gegevens	geen gegevens
Angela Cacace	Chief Scientific Officer	less than a year	geen gegevens	0.018% $ 304.9k
Jeff Boyle	Vice President of Investor Relations	3.8yrs	geen gegevens	geen gegevens
Jared Freedberg	General Counsel & Corporate Secretary	less than a year	geen gegevens	geen gegevens
Steve Weiss	Senior VP & Chief Human Resources Officer	no data	geen gegevens	geen gegevens
John Grosso	Senior Vice President of R&D Technical Operations	no data	geen gegevens	geen gegevens
Randy Teel	Chief Business Officer	less than a year	geen gegevens	0.021% $ 360.6k
John Northcott	Chief Commercial Officer	2.2yrs	geen gegevens	geen gegevens
Lisa Sinclair	Senior Vice President of Corporate Operations	2.2yrs	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ARVN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Houston	Chairperson	7.1yrs	US$7.63m	1.26% $ 21.9m
Ian Taylor	President of Research & Development and Chairman of Scientific Advisory Board	less than a year	US$2.73m	0.14% $ 2.4m
Edward Kennedy	Independent Director	6.3yrs	US$422.69k	0.068% $ 1.2m
Lillian Siu	Member of Scientific Advisory Board	5yrs	geen gegevens	geen gegevens
Leslie Norwalk	Independent Director	5.3yrs	US$424.99k	0.0060% $ 104.2k
Briggs W. Morrison	Lead Independent Director	6.3yrs	US$441.76k	0.035% $ 609.4k
Laurie Smaldone Alsup	Independent Director	4.9yrs	US$430.30k	0.0060% $ 104.2k
Adam Boxer	Member of Scientific Advisory Board	5yrs	geen gegevens	geen gegevens
Lennart Mucke	Member of Scientific Advisory Board	5yrs	geen gegevens	geen gegevens
Benjamin Neel	Member of Scientific Advisory Board	5yrs	geen gegevens	geen gegevens
John Young	Independent Director	2.2yrs	US$422.49k	0.0060% $ 104.2k
Linda Bain	Independent Director	4.3yrs	US$434.99k	0.0060% $ 104.2k

5.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ARVN wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

Arvinas Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Arvinas, Inc. Appoints Andrew Saik as Treasurer

Arvinas Announces Promotions of Ian Taylor to President of Research and Development and Angela Cacace to Chief Scientific Officer

Arvinas, Inc. Appoints Randy Teel as Chief Business Officer

Arvinas, Inc., Annual General Meeting, May 29, 2024

Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee

Arvinas, Inc. Announces Chief Financial Officer Changes

Recent updates

Consensus revenue estimates increase by 23%

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Arvinas, Inc.(NasdaqGS:ARVN) dropped from Russell Small Cap Comp Value Index

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Arvinas, Inc. Appoints Andrew Saik as Treasurer

Arvinas, Inc. Announces Presentations for Two of Its PROTAC Investigational Programs Targeting BCL6 and LRRK2

Arvinas Announces Promotions of Ian Taylor to President of Research and Development and Angela Cacace to Chief Scientific Officer

Arvinas, Inc. Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE)

Consensus revenue estimates increase by 17%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Arvinas, Inc. Appoints Randy Teel as Chief Business Officer

Arvinas, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$5.13 loss

Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee

Arvinas: Behind The Huge Rally

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$5.76 loss

Arvinas, Inc. announced that it has received $349.999871 million in funding from a group of investors

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. and Pfizer Inc. Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation for the Investigation of Vepdegestrant (Arv-471) for Monotherapy

Arvinas, Inc. Announces Appointment of Jared Freedberg as General Counsel

Arvinas, Inc. and Pfizer Inc. Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®?) and Plans to Expand Vepdegestrant Development Program

Price target decreased by 7.5% to US$55.82

New minor risk - Share price stability

Consensus estimates of losses per share improve by 13%

Price target decreased by 7.6% to US$55.80

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 10.0% to US$60.38

Arvinas, Inc. Announces the Presentation of Interim Data from the its Phase 1/2 Clinical Trial for Bavdegalutamide

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

Consensus revenue estimates increase by 17%

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

New minor risk - Share price stability

Arvinas, Inc. Announces Changes to its Board of Directors

Arvinas, Inc. Announces Interim Data from Phase 1/2 Dose Escalation and Expansion Trial of ARV-766

Consensus revenue estimates increase by 10%, EPS downgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

Consensus EPS estimates fall by 12%

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas Announces Changes to Its Board of Directors

Arvinas, Inc. Announces in Post-Hoc Analysis from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Expects VERITAC-2 Phase 3 Trial Population Achieve Clinical Benefit Rate of 62.5%

Price target decreased to US$83.90

Arvinas, Inc. Announces Initial Results from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Co-Developed with Pfizer Inc

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Arvinas, Inc. Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Arvinas, Inc. Announces Changes to its Board of Directors

Chief Medical Officer exercised options and sold US$69k worth of stock

Arvinas, Inc. Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas, Inc. Appoints John Northcott as Chief Commercial Officer

Arvinas: Still Holding, Just Not Buying More

Consensus EPS estimates fall by 12%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors